https://orcid.org/0000-0001-5854-9643
References
- Hartung DM. Health economics of disease-modifying therapy for multiple sclerosis in the United States. Ther Adv Neurol Disord. 2021;14:1756286420987031.
- Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639–647.
- Owens GM, Olvey EL, Skrepnek GH, et al. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013;19(1 Suppl A):S41–S53.
- National Multiple Sclerosis Society. Medications. [accessed 2022 Nov 8]. Available from: https://www.nationalmssociety.org/Treating-MS/Medications
- Kim Y, Krause TM, Blum P, et al. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis. Mult Scler Relat Disord. 2019;30:69–75.
- Slen BM. Infused therapies: cost savings benefits through home infusion [online]. Pharmacy Times; [accessed 2022 Aug 8]. Available from: https://www.pharmacytimes.com/view/infused-therapies-cost-savings-benefits-through-home-infusion
- Institute for Clinical and Economic Review [Internet]. Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: effectiveness and value. Final evidence report; 2017 [cited 2022 Apr 14]. Boston (MA): ICER. Available from https://icer.org/wp-content/uploads/2020/10/CTAF_MS_Evidence_Report_012617.pdf
- Dieguez G, Engel T, Jacobson N. Site of service and cost dispersion of infused drugs [online]; [accessed 2022 Jul 1]. Available from: https://www.milliman.com/en/insight/site-of-service-and-cost-dispersion-of-infused-drugs
- Nicholas J, Halpern R, Ziehn M, et al. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States. J Med Econ. 2020;23(8):885–893.
- Yang H, Duchesneau E, Foster R, et al. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J Med Econ. 2017;20(10):1056–1065.
- Esposito DB, Banerjee G, Yin R, et al. Development and validation of an algorithm to identify endometrial adenocarcinoma in US administrative claims data. J Cancer Epidemiol. 2019;2019:1938952.
- Ocrevus®. (Ocrelizumab) prescribing information; [accessed 2022 Aug 3]. Available from: https://www.gene.com/download/pdf/ocrevus_prescribing.pdf
- Tysabri®. (Natalizumab) prescribing information; [accessed 2022 Aug 3]. Available from: https://www.tysabrihcp.com/content/dam/commercial/tysabri/hcp/en_us/pdf/tysabri_prescribing_information.pdf
- Lemtrada®. (Alemtuzumab) prescribing information; [accessed 2022 Aug 3]. Available from: https://products.sanofi.us/Lemtrada/Lemtrada.html
- Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618–625.
- Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
- US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. [accessed 2022 Aug 8]. Available from: https://www.bls.gov/cpi/tables/supplemental-files/home.htm
- First data bank. Wholesale acquisition cost package pricing history. [accessed 2022 Jul 1]. Available from: https://www.fdbhealth.com/solutions/medknowledge-drug-database/medknowledge-drug-pricing
- Trebes N, Keenan C, Conway L. Payers are shifting where patients receive infusions. Here’s what that means for 4 key industry players [online]; 2020 [accessed 2022 Jul 1]. Available from: https://www.advisory.com/blog/2020/10/infusion-site-of-care
- Fronstin P. Location, location, location: spending differences for physician-administered outpatient medications by site of treatment. EBRI. 2021;536:1–13. [accessed 2022 Aug 3]. Available from: https://www.ebri.org/docs/default-source/ebri-issue-brief/ebri_ib_536_locationx3-19aug21.pdf?sfvrsn=cf6c3b2f_4
- Coles AJ, Arnold DL, Bass AD, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021;14:1756286420982134.